Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug;18(8):1255-64.
doi: 10.1016/j.bbmt.2011.12.581. Epub 2011 Dec 23.

Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure

César O Freytes  1 , Mei-Jie Zhang, Jeanette Carreras, Linda J Burns, Robert Peter Gale, Luis Isola, Miguel-Angel Perales, Matthew Seftel, Julie M Vose, Alan M Miller, John Gibson, Thomas G Gross, Philip A Rowlings, David J Inwards, Santiago Pavlovsky, Rodrigo Martino, David I Marks, Gregory A Hale, Sonali M Smith, Harry C Schouten, Simon Slavin, Thomas R Klumpp, Hillard M Lazarus, Koen van Besien, Parameswaran N Hari
Affiliations

Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure

César O Freytes et al. Biol Blood Marrow Transplant. 2012 Aug.

Abstract

We studied the outcome of allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning regimens (reduced-intensity conditioning and nonmyeloablative) in patients with non-Hodgkin lymphoma who relapsed after autologous hematopoietic stem cell transplantation. Nonrelapse mortality, lymphoma progression/relapse, progression-free survival (PFS), and overall survival were analyzed in 263 patients with non-Hodgkin lymphoma. All 263 patients had relapsed after a previous autologous hematopoietic stem cell transplantation and then had undergone allogeneic hematopoietic stem cell transplantation from a related (n = 26) or unrelated (n = 237) donor after reduced-intensity conditioning (n = 128) or nonmyeloablative (n = 135) and were reported to the Center for International Blood and Marrow Transplant Research between 1996 and 2006. The median follow-up of survivors was 68 months (range, 3-111 months). Three-year nonrelapse mortality was 44% (95% confidence interval [CI], 37%-50%). Lymphoma progression/relapse at 3 years was 35% (95% CI, 29%-41%). Three-year probabilities of PFS and overall survival were 21% (95% CI, 16%-27%) and 32% (95% CI, 27%-38%), respectively. Superior Karnofsky Performance Score, longer interval between transplantations, total body irradiation-based conditioning regimen, and lymphoma remission at transplantation were correlated with improved PFS. Allogeneic hematopoietic stem cell transplantation after lower-intensity conditioning is associated with significant nonrelapse mortality but can result in long-term PFS. We describe a quantitative risk model based on pretransplantation risk factors to identify those patients likely to benefit from this approach.

PubMed Disclaimer

Figures

Figure 1
Figure 1
a) Cumulative incidence of NRM and disease progression after RIC/NST in patients who experience relapse after auto-HSCT for NHL. b) Probabilities of PFS and OS after RIC/NST in patients who experienced relapse after auto-HSCT for NHL.
Figure 2
Figure 2
Probability of progression-free survival after RIC/NST in patients who experienced relapse after auto-HSCT for NHL, according to histology at the time of RIC/NST.
Figure 3
Figure 3
Probability of NRM after RIC/NST according to KPS in patients who experienced relapse after auto-HSCT for NHL.
Figure 4
Figure 4
Probability of relapse after RIC/NST in patients who experience relapse after auto-HSCT for NHL, according to time interval between transplants
Figure 5
Figure 5
Probability of PFS after RIC/NST in patients who experienced relapse after auto-HSCT for NHL according to KPS, interval between auto-HSCT and RIC/NST, use of TBI as part of conditioning regimen, and disease status at the time of RIC/NST.
Figure 6
Figure 6
Probability of PFS after RIC/NST in patients who experienced relapse after auto-HSCT for NHL according to conditioning regimen.
See this image and copyright information in PMC

Comment in

References

    1. Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001;19:406–413. - PubMed
    1. Lazarus HM, Loberiza FR, Jr, Zhang MJ, et al. Autotransplants for Hodgkin’s disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR) Bone Marrow Transplant. 2001;27:387–396. - PubMed
    1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–1826. - PubMed
    1. Smith SM, van Besien K, Carreras J, et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008;14:904–912. - PMC - PubMed
    1. Vandenberghe E, Pearce R, Taghipour G, Fouillard L, Goldstone AH. Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. J Clin Oncol. 1997;15:1595–1600. - PubMed

Publication types